The IDEXX IBR gB X3 Ab Test is an enzyme immunoassay for the detection of glycoprotein-B-specific antibodies to bovine herpesvirus-1 (BHV-1) in bovine serum, plasma and milk samples using IBR gB-specific monoclonal antibodies.

BHV-1 is the causative agent of infectious bovine rhinotracheitis (IBR), a highly contagious, infectious disease. Typical clinical signs associated with infection include respiratory disease, but the virus can also cause conjunctivitis, vulvovaginitis, abortions, encephalitis and balanoposthitis. The transition from primary manifestations of infection to a latent stage of persistency is often the source of spread after virus reactivation. Confirmation of exposure to BHV-1 is facilitated by a measurement of antibody.

- Highly sensitive blocking ELISA format
- Rapid test method—short (less than 4 hours) and overnight protocols
- Five-plate (strips) and 30-plate (solid) formats
- Ready-to-use reagents
- Easy to automate
- Compatible with xChekPlus® software

To demonstrate equivalence of test performances between the current IDEXX IBR gB X2 Ab Test (referred to as the SOP) and the new IDEXX IBR gB X3 Ab Test, serum samples were collected from a gE vaccinated animal in Germany that was determined to be positive. Samples were collected Day 3–Day 60 postvaccination and then tested on three lots of the IDEXX IBR gB X3 Ab Test and three lots of the IDEXX IBR gB X2 Ab Test (SOP).

**Interpretation of results:** Values <45% are negative; values between 45–55% are suspect; values >55% are positive.

**Conclusion:** Specificity reached 99.8% for both the IDEXX IBRgB X3 Ab Test and IDEXX IBRgB X2 Ab Test in this large and varied set of negative samples.

Serum samples from Switzerland (n=594)—5 populations
Serum samples from Spain (n=316)—2 populations
Plasma samples from Switzerland (n=98)—1 population
Plasma samples from Austria (n=240)—1 population

Total N=1,315

**Specificity: European negative population**

**Sensitivity: Temporal Sera**
Sensitivity

To demonstrate equivalence of test performances between the current IDEXX IBR gB X2 Ab Test (referred to as the SOP) and the new IDEXX IBR gB X3 Ab Test, test results from German, French and European reference samples were compared.

Interpretation of results: Values <45% are negative; values between 45–55% are suspect; values >55% are positive.

Conclusion: Performance of the IDEXX IBRgB X3 Ab Test was equivalent to the IDEXX IBRgB X2 Ab Test. Both tests demonstrated 100% agreement with expected results, including samples known to have BHV-1 antibody titers that were detected as positive samples.

For more information about the IDEXX IBR gB X3 Ab Test, contact your IDEXX representative, or visit idexx.com/ibr.